|1.||Serhan, Charles N: 20 articles (01/2013 - 03/2005)|
|2.||Arita, Makoto: 11 articles (10/2015 - 03/2005)|
|3.||Van Dyke, Thomas E: 9 articles (05/2015 - 11/2007)|
|4.||Hong, Song: 6 articles (08/2009 - 03/2005)|
|5.||Chiang, Nan: 5 articles (01/2013 - 03/2005)|
|6.||Levy, Bruce D: 5 articles (01/2012 - 08/2008)|
|7.||Gjorstrup, Per: 4 articles (04/2015 - 10/2010)|
|8.||Ji, Ru-Rong: 4 articles (03/2013 - 05/2010)|
|9.||Xu, Zhen-Zhong: 4 articles (03/2013 - 05/2010)|
|10.||Fredman, Gabrielle: 4 articles (01/2013 - 08/2008)|
11/01/2012 - "Based on its proven efficacy in models of chronic inflammation, this study investigated the efficacy of resolvin E1 in a murine model of dry eye. "
05/01/2014 - "RvE1 was more effective in reducing inflammation at earlier stages. "
01/01/2014 - "RvE1 is locally generated in response to inflammation where it enhances the resolution phase of inflammation by diminishing neutrophil chemotaxis and by enhancing nonphlogistic macrophage-directed clearance of apoptotic neutrophils. "
09/10/2010 - "RvE1 treatment at the time of either OVA sensitization or challenge also improved AHR and airway inflammation. "
03/01/2011 - "This is supported in a study in which topical RvE1 resulted in decreased inflammation in a mouse dry eye model. "
02/01/2006 - "Consistent with these potent actions, topical application of RvE1 in rabbit periodontitis conferred dramatic protection against inflammation induced tissue and bone loss associated with periodontitis."
01/01/2014 - "RvE1 was also found to be effective in preventing and restoring bone loss in the inflammatory bone disease periodontitis. "
05/01/2015 - "RvE1, used as an oral/topical agent, significantly diminished atherogenesis and prevented periodontitis (P<0.05). "
02/01/2006 - "RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis."
05/01/2015 - "The results suggest that oral/topical RvE1 attenuates enhanced atherogenesis induced by periodontitis and prevents vascular inflammation and atherogenesis in the absence of periodontitis. "
03/15/2007 - "In vivo anti-inflammatory actions of RvE1 were sharply reduced in BLT1 knockout mice when given at low doses (100 ng i.v.) in peritonitis. "
01/01/2010 - "RvE1 reduces inflammation in several types of animal models including peritonitis and retinopathy and blocks human neutrophil transendothelial cell migration. "
01/15/2013 - "In zymosan-initiated peritonitis, neutrophil polymorphonuclear leukocyte infiltration in response to RvE1 was limited requiring log order lower doses in chemR23tg mice. "
08/11/2006 - "At a concentration where RvE1 potently reduced polymorphonuclear leukocyte (PMN) recruitment in zymosan-induced peritonitis, 18-oxo-RvE1 was devoid of activity. "
05/24/2005 - "Here, we obtained evidence for reduced leukocyte infiltration in a mouse peritonitis model, where the administration of EPA and aspirin initiated the generation of RvE1 in the exudates. "
|4.||Atopic Dermatitis (Atopic Eczema)
|5.||Bone Diseases (Bone Disease)
|1.||Interleukin-12 (IL 12)
|3.||5S,12R,18R- trihydroxy- 6Z,8E,10E,14Z,16E- eicosapentaenoic acid
|5.||Omega-3 Fatty Acids (Omega 3 Fatty Acids)
|8.||Prostaglandins E (PGE)
|10.||Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)